Trial Outcomes & Findings for Feasibility of Performing Peripheral Pulmonary Lesion Biopsy Using Robotic Bronchoscopy-Guided Cryoprobe (NCT NCT05399082)

NCT ID: NCT05399082

Last Updated: 2024-10-17

Results Overview

Number of tissue samples that are considered by the bronchoscopist as adequate for further pathological analysis

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

30 participants

Primary outcome timeframe

Baseline

Results posted on

2024-10-17

Participant Flow

Participant milestones

Participant milestones
Measure
Standard Forceps Biopsy First, Then Research Cryoprobe Biopsy
Subjects who received standard forceps biopsy either first or second during their biopsy of lung lesions. Standard forceps biopsy first, then crossover to receive the research cryoprobe biopsy during the procedure. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue Standard forceps biopsy: Biopsy forceps used to collect tissue
Research Cryoprobe Biopsy First, Then Standard Forceps Biopsy
Subjects who received the research cryoprobe biopsy first or second during their biopsy of lung lesions. Research cryoprobe biopsy first, then crossover to receive the standard forceps biopsy during the procedure. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue Standard forceps biopsy: Biopsy forceps used to collect tissue
First Intervention
STARTED
15
15
First Intervention
COMPLETED
15
15
First Intervention
NOT COMPLETED
0
0
Second Intervention
STARTED
15
15
Second Intervention
COMPLETED
15
15
Second Intervention
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Feasibility of Performing Peripheral Pulmonary Lesion Biopsy Using Robotic Bronchoscopy-Guided Cryoprobe

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Standard Forceps Biopsy First, Then Research Cryoprobe Biopsy
n=15 Participants
Subjects who received standard forceps biopsy either first or second during their biopsy of lung lesions. Standard forceps biopsy first, then crossover to receive the research cryoprobe biopsy during the procedure. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue Standard forceps biopsy: Biopsy forceps used to collect tissue
Research Cryoprobe Biopsy First, Then Standard Forceps Biopsy
n=15 Participants
Subjects who received the research cryoprobe biopsy first or second during their biopsy of lung lesions. Research cryoprobe biopsy first, then crossover to receive the standard forceps biopsy during the procedure. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue Standard forceps biopsy: Biopsy forceps used to collect tissue
Total
n=30 Participants
Total of all reporting groups
Age, Continuous
70.3 years
STANDARD_DEVIATION 9.23 • n=5 Participants
70.2 years
STANDARD_DEVIATION 7.11 • n=7 Participants
70.3 years
STANDARD_DEVIATION 8.4 • n=5 Participants
Sex: Female, Male
Female
8 Participants
n=5 Participants
4 Participants
n=7 Participants
12 Participants
n=5 Participants
Sex: Female, Male
Male
7 Participants
n=5 Participants
11 Participants
n=7 Participants
18 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
2 Participants
n=7 Participants
2 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
15 Participants
n=5 Participants
13 Participants
n=7 Participants
28 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
14 Participants
n=5 Participants
15 Participants
n=7 Participants
29 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
15 participants
n=5 Participants
15 participants
n=7 Participants
30 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline

Number of tissue samples that are considered by the bronchoscopist as adequate for further pathological analysis

Outcome measures

Outcome measures
Measure
Standard Forceps Biopsy
n=30 Participants
Subjects who received standard forceps biopsy either first or second during their biopsy of lung lesions. Standard forceps biopsy: Biopsy forceps used to collect tissue
Research Cryoprobe Biopsy
n=30 Participants
Subjects who received the research cryoprobe biopsy first or second during their biopsy of lung lesions. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
Ability to Successfully Obtain Sample
123 tissue samples
130 tissue samples

SECONDARY outcome

Timeframe: Biopsy procedure, approximately 3 hours

Total time of biopsy procedure from first insertion of probe into robotic sheath to removal of specimens.

Outcome measures

Outcome measures
Measure
Standard Forceps Biopsy
n=30 Participants
Subjects who received standard forceps biopsy either first or second during their biopsy of lung lesions. Standard forceps biopsy: Biopsy forceps used to collect tissue
Research Cryoprobe Biopsy
n=30 Participants
Subjects who received the research cryoprobe biopsy first or second during their biopsy of lung lesions. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
Duration of Biopsy Procedure
41 minutes
Interval 30.0 to 53.0
41 minutes
Interval 21.0 to 54.0

SECONDARY outcome

Timeframe: Biopsy procedure, approximately 60 seconds

Population: This outcome measure was only collected and analyzed for the Research cryoprobe biopsy arm

Total freezing time for cryoprobe biopsies, measured in seconds

Outcome measures

Outcome measures
Measure
Standard Forceps Biopsy
Subjects who received standard forceps biopsy either first or second during their biopsy of lung lesions. Standard forceps biopsy: Biopsy forceps used to collect tissue
Research Cryoprobe Biopsy
n=30 Participants
Subjects who received the research cryoprobe biopsy first or second during their biopsy of lung lesions. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
Freezing Time for Cryoprobe Biopsies
4.54 seconds
Standard Deviation 0.91

SECONDARY outcome

Timeframe: Biopsy procedure, approximately 3 hours

One attempt is defined as insertion of the biopsy probe into the robotic sheath, activation/employment of the biopsy mechanism at the target site and retrieval via the robotic sheath. A biopsy attempt is successful if a tissue sample that is considered by the bronchoscopist to be adequate for further pathological analysis can be retrieved.

Outcome measures

Outcome measures
Measure
Standard Forceps Biopsy
n=30 Participants
Subjects who received standard forceps biopsy either first or second during their biopsy of lung lesions. Standard forceps biopsy: Biopsy forceps used to collect tissue
Research Cryoprobe Biopsy
n=30 Participants
Subjects who received the research cryoprobe biopsy first or second during their biopsy of lung lesions. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
Number of Successful Biopsy Attempts
123 successful attempts
130 successful attempts

SECONDARY outcome

Timeframe: Pathology review, approximately 1 day

Population: Data was not collected nor analyzed due to inadequate tissue size, volume, and quality, no data were collected for this Outcome Measure

Pathologic description ranging from insufficient to diagnostic material

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pathology review, approximately 1 day

Population: Data was not collected nor analyzed due to inadequate tissue size, volume, and quality, no data were collected for this Outcome Measure

Defined as the ability of the pathologist to make a diagnostic statement based on the histological analysis of the obtained tissue samples. Graded 1-4 with 1 being insufficient tissue and 4 being diagnostic material.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pathology review, approximately 1 day

Population: Data was not collected nor analyzed due to inadequate tissue size, volume, and quality, no data were collected for this Outcome Measure

The total histological area of the biopsy samples. Measured in (mm\^2)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pathology review, approximately 1 day

Population: Data was not collected nor analyzed due to inadequate tissue size, volume, and quality, no data were collected for this Outcome Measure

The total percent area of crush artifacts identified in the biopsy samples (percent total area)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pathology review, approximately 1 day

Population: Data was not collected nor analyzed due to inadequate tissue size, volume, and quality, no data were collected for this Outcome Measure

The total percent area of other pathologic artifacts identified in the tissue biopsy samples that obscure pathological assessment (percent total area)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pathology review, approximately 1 day

Population: Data was not collected nor analyzed due to inadequate tissue size, volume, and quality, no data were collected for this Outcome Measure

The total percent area of different tissue types identified in the tissue biopsy samples. Defined as the total of alveoli, bronchus, mucus, blood, and target tissue (percent total area)

Outcome measures

Outcome data not reported

Adverse Events

Standard Forceps Biopsy

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Research Cryoprobe Biopsy

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Standard Forceps Biopsy
n=30 participants at risk
Subjects who received standard forceps biopsy either first or second during their biopsy of lung lesions. Standard forceps biopsy: Biopsy forceps used to collect tissue
Research Cryoprobe Biopsy
n=30 participants at risk
Subjects who received the research cryoprobe biopsy first or second during their biopsy of lung lesions. Cryoprobe biopsy: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
Injury, poisoning and procedural complications
Minor bleeding
10.0%
3/30 • Number of events 3 • Adverse events were collected for each subject from baseline until completion of the standard of care post procedure follow-up for approximately 2 weeks
6.7%
2/30 • Number of events 3 • Adverse events were collected for each subject from baseline until completion of the standard of care post procedure follow-up for approximately 2 weeks

Additional Information

Ryan M. Kern, M.D.

Mayo Clinic

Phone: 507-266-3958

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place